How does physiology complement anatomy

It is an acute phase reactant produced in the liver and binds to the carbohydrates on the surfaces of many pathogens. The steps for the lectin pathway are:. The complement system might play a role in diseases with an immune component, such as Barraquer-Simons Syndrome, asthma, lupus erythematosus, glomerulonephritis, various forms of arthritis, autoimmune heart disease, multiple sclerosis, inflammatory bowel disease, ischemia-reperfusion injuries, and rejection of transplanted organs.

Additionally, deficiencies in complement proteins produced in the liver can lead to a form of primary congenital immunodeficiency, in which the body is more susceptible to disease, particularly autoimmune diseases and severe bacterial infections. Learning Objectives Describe the role of the complement system in immunity. Key Points The complement system helps antibodies and phagocytic cells clear pathogens from an organism. The complement system consists of a number of small proteins produced by the acute phase reaction in the liver during inflammation.

The complement system might play a role in diseases with an immune component and those of the central nervous system. Complement protein deficiency is a form of primary immunodeficiency. The classical complement pathway starts with antibody binding, which causes a cascade reaction of complement proteins that gradually form a membrane attack complex.

How many molecules are in the human body? What are five different ways the body maintains homeostasis? What organs are located on the left side of your body below the rib cage? How can the heart beat when it is outside of the body?

What is the "trunk" of the body? Where is it located? These activation fragments will be generated at sites of activation of the coagulation cascade.

Complement-independent cleavage of C3 by plasmin has also been suggested in the literature — The fragments generated by plasmin-mediated cleavage C3a-like, C3b-like, iC3b-like, C3c-like, and C3dg-like are similar, but not identical to fragments generated by the complement cascade and are biologically active.

Activation of the terminal complement pathway results in formation of MAC that form large, 10 nm wide, pores in the target membrane These complexes are formed when C5 is cleaved into C5b by the C5 convertase.

Upon cleavage, C5b undergoes a dramatic conformational change, similar to C3b, but with a TED domain ending up only halfway the distance to the MG ring Figure 12 C5b-7 is lipophilic and binds to the cell membrane C8 is the first component to penetrate the lipid bilayer upon interaction with the forming MAC.

This resemblance suggests a common membrane perforation mechanism for MAC, perforin in the mammalian immune system, and bacterial pore-forming proteins A single MAC contains up to 18 C9 molecules forming a tubular channel. However, only one or two C9 molecules are sufficient to form functional pores , Each functional MAC is sufficient to lyse by colloid osmosis in the membrane of metabolically inert cells, like erythrocytes or liposomes Gram-negative bacteria are also susceptible to complement killing, in particular the meningitis causing Neisseria species , Individuals deficient in terminal complement components are at increased risk for recurrent meningitis.

Gram-positive bacteria have an extremely thick cell wall that MAC cannot penetrate leaving them resistant to complement elimination. Metabolically active nucleated cells are also resistant to lysis by complement , In order to induce killing in these cells, multiple MACs must be inserted in the cell membrane together with coordination of calcium flux and not well-understood signal transduction Once MACs have inserted in these cells, calcium flux is induced in the pore from the extracellular space or is released from intracellular stores Subsequently, multiple still not well-known signaling pathways are activated leading to cell proliferation or apoptosis, which is dependent on the targeted cell type and experimental conditions.

Membrane-attack-complex formation is tightly regulated to avoid accidental host cell damage and activation Figure C8 was suggested to play a dual role in MAC formation and regulation. In the absence of a cell membrane, the binding of C8 to C5b-7 induces conformation changes that result in a loss of ability to form pores, causing it to act as a MAC inhibitor If soluble dead-end products sC5b-7, sC5b-8, and sC5b-9 are generated in fluid phase and do not bind to a membrane, they are scavenged by clusterin and vitronectin.

These two regulators bind below the C5b-9 arc rendering it water soluble and preventing membrane binding , — CD59 does not bind free C8 and C9, but does interact with the MACPF domain of each protein upon conformational changes associated with C5b-9 complex formation — Furthermore, the lytic terminal complex of complement C5b-9 can be removed within minutes of its deposition on the membrane of target cells either by shedding via membrane vesicles exocytosis or by internalization and degradation — The anaphylatoxins, C3a and C5a, are constantly released during complement activation.

These small 10—14 kDa peptides play a critical role in supporting inflammation and activation of cells that express anaphylatoxin receptors To enhance inflammation, anaphylatoxins recruit immune cells to the site of complement activation and induce oxidative bursts on macrophages , , eosinophils , and neutrophils , However, some studies challenged the concept for the pro-inflammatory role of C3a.

C3a has a more complex function, depending on the context, with a balance between pro- and anti-inflammatory roles. The highlight anti-inflammatory properties of C3a re-evaluate its physiological role during inflammation Furthermore, C3a and C5a induce histamine production by basophils , and mast cells to provoke vasodilatation. C5a also recruits T-cells and myeloid-derived suppressor cells that constitutively express C5aR.

Although the functional activity of C4a is debated, it has been reported to activate macrophage and monocytes , However, a lack of cognate C4a receptor identification and unreproducible data warrant further studies to determine the physiological role of C4a. Structural data show that both human C3a and C5a adopt an alpha-helical conformation with four- and three-helical bundles, respectively Figure The C5a crystal structure has a core domain constituted as an antiparallel alpha-helical bundle and the C-terminal domain links the core domain by a short loop containing two adjacent arginines in position 62 and 74 that both interact at the same binding site on the receptor.

In human plasma, these two fragments are rapidly converted by carboxypeptidase N to C3a desArg and C5a desArg by cleavage at the C-terminal arginine , C3a desArg has a very similar structure to C3a , but is incapable of binding to C3aR. The alpha1-helix of C5a desArg is detached at the three others alpha-helices In contrast, murine C5a desArg is as potent as the murine C5a upon binding to C5aR on murine cells , which could be explained by the lack of major structural changes in the murine C5a desArg, compared to C5a.

Both murine proteins form a four-helix bundle, contrary to the human C5a desArg, which adopts a three-helix bundle conformation upon cleavage of the terminal Arg residue. These inter-species differences need to be taken into account during analysis of in vivo experiments. Complement anaphylatoxins. C3a and C5a have a four and three helical bundle topology. Mouse C5a in the square is different from its human counterpart, because it has four helical bundle structure.

These anaphylatoxins bind to G protein-coupled receptors C3aR and C5aR and stimulate pro-inflammatory signaling pathways. The C3a-binding site of C3aR is located in the large second extracellular loop that contains a sulfotyrosine , which is critical for C3a docking There are two sites in C5aR that are essential for C5a binding. The first sight consists of basic residues from human C5a that interact with sequences rich in aspartic residues located on N-terminal extracellular domain of C5aR The second site is in a binding pocket located near the fifth transmembrane domain and interacts with the C-terminal region of human C5a Then, two distinct clusters of hydrophobic residues allow a molecular switch in C5aR leading to G protein activation This mechanism exposes preserved residues clustered in two intracellular and two transmembrane domains that participate to the initial interaction with G proteins The second extracellular loop plays a role of a negative regulator of C5aR activation and may stabilize the inactivated form of the receptor C5L2 is again composed of seven transmembrane domains, however it is not coupled with G protein due to an amino acid alteration at the end of the third transmembrane in the DRY sequence C5a has lower affinity to C5L2 compared to C5a desArg and recently it has been demonstrated that C5L2 is a negative regulator of anaphylatoxin activity It has also been reported that C5L2 and C5aR form a heterodimer and this complex induces internalization of C5aR upon C5a binding This internalization is essential for the induction of the late stage of ERK signaling , Complement participates actively in the opsonization of pathogens and dying host cells, in addition to the clearance of immune complexes.

Recognition molecules in the CP and LP, as well as cleavage fragments of C3, opsonize the target structure and serve as bridging molecules with receptors on the surface of the phagocytes. Depending on the type of the opsonin present C3b, iC3b, or C3d , the phagocyte will generate a pro-inflammatory response or tolerogenic suppression. CR1 is expressed on monocytes, macrophages, neutrophils, erythrocytes, and renal podocytes, CR2 is found on B-cells, CR3 and CR4 are expressed by macrophages, monocytes, dendritic cells, neutrophils, and NK cells and CRIg has restricted expression and is found mainly on Kupffer cells in the liver and resident tissue macrophages Interestingly, the expression of CRIg on macrophages in inflamed tissue is lower compared to macrophages outside of an inflammatory area Complement receptors.

CR1 is composed of CCP domains and is expressed primarily by immune cells and erythrocytes. Apart from being cofactor of FI, CR1 is also a complement receptor facilitating immune complex clearance and phagocytosis. CR1 interacts with C3b. CRIg has immunoglobulin-like structure in its C3b recognition domain. It serves as a co-stimulatory molecule for the B-cell receptor upon binding C3d-opsonized pathogen. C3d serves as a molecular adjuvant by lowering the threshold for B-cell activation by —10,fold The TED domain of C3 has a completely different conformational environment in the native protein as compared to its degradation products C3b, iC3b, C3dg, and C3d.

Two different crystal structures had been proposed for the complex CR2:C3d; the first one, described in by Szakonyi et al. Contrary to this result, biochemical studies showed that mutations on several basic residues on CCP1 domain affected C3d binding to CR2 In , a second structure was proposed in agreement with the mutagenesis data where both CCP1 and CCP2 are involved in the interaction Figure One possible explanation for the discrepancy between structures could be due to the high concentration of zinc in the crystallization buffer from leading to a non-physiological complex.

They bind multiple ligands participating in phagocytosis, cell adhesion to the extracellular matrix, leukocyte trafficking, synapse formation, and co-stimulation. Ligand binding and signaling through integrin receptors is governed by a complex cascade of conformational changes, known as inside-out signaling Upon ligand binding, another signal is transmitted outside-in, leading to raid cellular response, including actin remodeling, phagocytosis, degranulation, or slow responses involving protein neosynthesis.

CR3 and to lesser extent CR4 are essential for phagocytosis of C3 fragments, opsonized immune complexes, and pathogens CR3 and CR4 differ in their profile of recognized C3 fragments because both receptors bind to iC3b, but CR3 recognizes C3d, while CR4 binds to C3c, suggesting that the two receptors have distinct binding sites on the iC3b molecule Figure 14 , The architecture of the complex has only been observed at low resolution, by electron microscopy and displays a CR4 binding site at the interface between MG3 and MG4 Immunoglobulin superfamily receptor CRIg is a CR expressed on macrophages and Kupffer cells in the liver that binds to C3b and iC3b Figure 14 and mediates the phagocytosis of opsonized particles and pathogens , The importance of the complement system in physiology is illustrated by the severe and life threatening diseases occurring due to inefficient or excessive complement activity.

Abnormal complement activity is associated with many inflammatory, autoimmune, neurodegenerative, and age-related diseases. Here, we will describe the role of complement dysfunction in aHUS. The aHUS is a rare thrombotic microangiopathy that predominates in the kidney. This thrombotic microangiopathy is different than typical HUS and thrombotic thrombocytopenic purpura because it is not associated with infection by Shiga toxin-producing bacteria or ADAMST13 deficiency, respectively.

In contrast, typical HUS is predominantly a pediatric disease and has a favorable renal outcome. Renal failure is a result of platelets rich microthrombi, formed in the small vessels capillaries and arterioles of the kidney resulting in a prothrombotic state. The hallmark of the aHUS is the association with alternative complement pathway mutations Figure 15 A. Endothelial damage is known to be related to complement dysregulation.

Understanding aHUS using structure—function relationships. A The role of complement alternative pathway in the physiopathology of aHUS. Mutations in the components of the C3 convertase C3 and FB induce the formation of overactive C3 convertase or a convertase that is resistant to regulation. In both cases, the complement cascade is activated on glomerular endothelial cell surface leading to endothelial damage, thrombosis, erythrocyte lysis, and aHUS. FH disease-associated mutations that decrease only C3b-binding are indicated in orange and mutations decreasing both C3b and GAG binding are in magenta.

C C3 mutations found in aHUS patients. The majority of the mutations in red are not randomly distributed, but mapped to the FH binding sites on C3b. The importance of screening for mutations in complement factors can be observed in the examples of FH and C3. These mutations affect either the interaction with C3b, GAG, or both ligands leading to impaired cell surface protection against complement attack [ , , ; summarized in Ref.

A similar phenomenon is observed with C3 mutations found in aHUS. Functional analysis revealed that mutations located in the FH-binding sites resulted in decreased FH binding, thus showing the link with aHUS.

Currently, there is a debate as to whether or not in physiological conditions FH CCP20 can interact with an adjacent C3d molecule , , It is possible the observed interaction between the second molecule C3d and FH CCP20 may be a crystallization artifact and in turn the functional consequences of certain aHUS associated FH and C3 mutations will be more difficult to explain.

This case exemplifies how structural analyses can aid in understanding disease physiopathology and how disease physiopathology improves our understanding of complement. Disease-associated mutations also has resulted in the mapping of the MCP binding site on C3b. Experimental and structural analysis revealed that for FH and C3 almost all studied genetic changes mapped to the ligand binding site and had clear functional consequences.

Mutations in FB were located in multiple domains of the protein and in more than half of the cases they were far from any known binding sites Mutations located within the C3b-binding site did induced formation of an overactive C3 convertase or a convertase resistant to regulation — The mutations far from this binding interface showed no functional defect as observed by FB functional tests As shown for the majority of complement mutations in aHUS, mapping of disease-associated mutations together with detailed functional analysis should be performed to understand the mechanism of complement dysregulation associated with a disease.

We have described in depth the known molecular mechanisms of the complement system and this unleashes many possibilities for rational design of complement inhibitors for treatment of disease , Here, we will give a few examples that illustrate this concept. Blockade of the late effector functions of complement can be obtained if the cleavage of C5 by the two C5 convertases is prevented. The therapeutic monoclonal antibody, Eculizumab, targets human C5 and blocks cleavage by C5 convertases The Eculizumab binding epitope on C5 interacts with the contact interface between C5 and the C5 convertase preventing the entry of C5 into the C5 convertase and blocking further cleavage and generation of the bioactive fragments C5a and C5b Eculizumab blocks the terminal complement pathway but leaves the C3 convertases unaffected.

Eculizumab showed significant improvement in clinical outcome and has been accepted for treatment of complement-mediated diseases including paroxysmal nocturnal hemoglobinuria PNH and aHUS , and clinical trials are ongoing for other diseases.

In order to control complement at an earlier step, inhibitors acting at the level of C3 have also been designed. Compstatin is a residue peptide that is being tested pre-clinically. It binds to C3 and blocks its cleavage , Compstatin binds to MG4 and MG5 of C3c and C3b where it undergoes a large conformational change upon interaction causing steric hindrance of the substrate C3 to the convertase complexes and blocking complement activation and amplification.

Compstatin has shown efficacy in complement blocking in vitro and in animal models including extracorporeal circulation , sepsis , and PNH Both Compstatin and Eculizumab are species-specific and act only in humans and monkeys, but not in mice or rats, reflecting subtle differences in the structure of human and murine complement components.

Another strategy of rational design of complement inhibitors is to target the regulatory domains of FH or CR1 to the cell surface via potent C3b, iC3b, C3d, or membrane recognition domains, derived from FH or CR2.

Currently, we know that complement is not only a simple lytic system, but rather a powerful innate immune surveillance tool, serving as a sentinel against pathogens, modulator of the adaptive immune response, and as a regulator of host homeostasis. This cascade of enzymatic reactions is driven by conformational changes induced after a recognition event assuring that complement will be activated only when and where needed. This special and temporal control of complement activation is guaranteed also by the high specificity and selectivity of the enzymatic reactions, where the involved enzymes cleave only a single substrate and have a single ligand-binding site.

In contrast to this high specificity of the propagation of the chain reaction, complement activation relies on target patterns binding by versatile recognition molecules, such as C1q, MBL, ficolins, and properdin. The activation of the three complement pathways leads to the generation of C3b, the Swiss army knife of complement, which interacts with a large variety of ligands and receptors with multiple distinct binding sites. The balance of these interactions determines whether full-blown activation will occur by the amplification loop of the complement pathways, with a generation of one of the most potent inflammatory mediators C5a or the effect will be attenuated by the C3b breakdown cycle.

Again, the attenuation relies in large part on the capacity of a versatile recognition molecule FH to discriminate between self and non-self and to stop the amplification loop. C3b and C3 H 2 O may bind to the cell surface via proteins-platforms, like properdin and P-selectin.

The knowledge of these molecular mechanisms that has been accumulated during recent years has allowed for better understanding of complement-related diseases. It also opens up the possibility for a rational design of novel molecules with therapeutic potential to control steps in the complement cascade.

Clinical application of the anti-C5 blocking antibody Eculizumab has already demonstrated that controlling complement can revolutionize the treatment of patients with overactive complement-mediated diseases. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. We are grateful to Dr. Whenever atomic coordinates are available for a given protein in Protein Data Bank, they were used for the representation of the protein on the figures.

Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11 — Complement — tapping into new sites and effector systems. Nat Rev Immunol 14 — Complement system part II: role in immunity. Front Immunol Lachmann PJ, Halbwachs L. The influence of C3b inactivator KAF concentration on the ability of serum to support complement activation. Clin Exp Immunol 21 — PubMed Abstract Google Scholar. Formation of the initial C3 convertase of the alternative complement pathway.

Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med — Nilsson B, Nilsson Ekdahl K.

The tick-over theory revisited: is C3 a contact-activated protein? Immunobiology — Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties. Biochemistry 20 — Self-association and domain rearrangements between complement C3 and C3u provide insight into the activation mechanism of C3.

Biochem J — Structural transitions of complement component C3 and its activation products. A revised mechanism for the activation of complement C3 to C3b: a molecular explanation of a disease-associated polymorphism. J Biol Chem 4 — J Immunol — Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation.

Biochem J Pt 2 — The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci 6 — Continual low-level activation of the classical complement pathway. C1q and phagocytosis: the perfect complement to a good meal. J Leukoc Biol 92 — Opsonization of apoptotic cells by autologous iC3b facilitates clearance by immature dendritic cells, down-regulates DR and CD86, and up-regulates CC chemokine receptor 7.

C3 opsonization regulates endocytic handling of apoptotic cells resulting in enhanced T-cell responses to cargo-derived antigens. Complement protein C1q bound to apoptotic cells suppresses human macrophage and dendritic cell-mediated Th17 and Th1 T cell subset proliferation.

J Leukoc Biol 97 — Opsonization with C1q and mannose-binding lectin targets apoptotic cells to dendritic cells. Walport MJ. Second of two parts.

N Engl J Med —4. Harboe M, Mollnes TE. The alternative complement pathway revisited. J Cell Mol Med 12 4 — Lachmann PJ. The amplification loop of the complement pathways. Adv Immunol — C1q and its growing family. Biochemistry 44 — Structural and functional anatomy of the globular domain of complement protein C1q. Immunol Lett 95 — Biochemistry 47 — Mutational analyses of the recombinant globular regions of human C1q A, B, and C chains suggest an essential role for arginine and histidine residues in the C1q-IgG interaction.

J Immunol —8. Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human C1q A, B, and C chains. Biochemistry 45 — Existence of different but overlapping IgG- and IgM-binding sites on the globular domain of human C1q. Interaction of the globular domain of human C1q with Salmonella typhimurium lipopolysaccharide.

Biochim Biophys Acta —6. Interaction between complement subcomponent C1q and the Klebsiella pneumoniae porin OmpK Infect Immun 64 — The human c1q globular domain: structure and recognition of non-immune self ligands.

Front Immunol 2 Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur J Immunol 32 — C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition. Investigations on the C1q-calreticulin-phosphatidylserine interactions yield new insights into apoptotic cell recognition.

J Mol Biol — The lectin-like activity of human C1q and its implication in DNA and apoptotic cell recognition. FEBS Lett —6. Interaction of the C1 complex of complement with sulfated polysaccharide and DNA probed by single molecule fluorescence microscopy. Eur J Biochem — Human and pneumococcal cell surface glyceraldehydephosphate dehydrogenase GAPDH proteins are both ligands of human C1q protein. J Biol Chem — Annexin A2 and A5 serve as new ligands for C1q on apoptotic cells.

C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. Interaction of C1q with the receptor calreticulin requires a conformational change in C1q.

Scand J Immunol 59 — Relative contribution of c1q and apoptotic cell-surface calreticulin to macrophage phagocytosis. J Innate Immun 6 — A novel human serum lectin with collagen- and fibrinogen-like domains that functions as an opsonin.

Identification of the C1q-binding sites of human C1r and C1s: a refined three-dimensional model of the C1 complex of complement. J Biol Chem —8. The two major oligomeric forms of human mannan-binding lectin: chemical characterization, carbohydrate-binding properties, and interaction with MBL-associated serine proteases.

J Immunol —7. A second serine protease associated with mannan-binding lectin that activates complement. Nature — Structure and activation of the C1 complex of complement: unraveling the puzzle. Trends Immunol 25 — Complement is activated by IgG hexamers assembled at the cell surface. Science —3. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts.

Blood — Antibody density on rat red cells determines the rate of activation of the complement component C1. Eur J Immunol 15 — IgGs are made for walking on bacterial and viral surfaces. Nat Commun 5 Front Immunol 5 Heme interacts with c1q and inhibits the classical complement pathway. Structural biology of C1: dissection of a complex molecular machinery.

Immunol Rev — Structure, function and molecular genetics of human and murine C1r. Structural biology of the C1 complex of complement unveils the mechanisms of its activation and proteolytic activity. Mol Immunol 39 — Monomeric structures of the zymogen and active catalytic domain of complement protease c1r: further insights into the c1 activation mechanism.

Structure 10 — Medical and dental students also learn through the dissection and inspection of cadavers. A thorough working knowledge of anatomy is required for all medical professionals, especially surgeons and doctors working in diagnostic specialties such as radiology.

Physiology is the study of how the components of the body function, and biochemistry is the study of the chemistry of living structures. Together with anatomy, these are the three primary disciplines within the field of human biology. Anatomy provides information about structure, location, and organization of different parts of the body that is needed to truly understand physiology.

Together, anatomy and physiology explain the structure and function of the different components of the human body to describe what it is and how it works. Physiology is the science of the normal function of living systems. Physiology studies the processes and mechanisms that allow an organism to survive, grow, and develop. Physiological processes are the ways in which organ systems, organs, tissues, cells, and biomolecules work together to accomplish the complex goal of sustaining life.

Physiological mechanisms are the smaller physical and chemical events that make up a larger physiological process. Human physiology studies the functions of humans, their organs and cells, and how all of these functions combine to make life, growth, and development possible. The drawing is based on the correlations of ideal human proportions with geometry described[4] by the ancient Roman architect Vitruvius in Book III of his treatise De Architectura.

This resistance stabilizes the body by regulating the internal environment, even as the external environment changes. A stable internal environment is needed for normal physiological function and survival of a living system. Maintaining a stable internal environment requires constant monitoring, mostly by the brain and nervous system. The brain, more specifically the hypothalamus, receives information from the body and responds appropriately through the release of chemical messengers such as neurotransmitters, catecholamines, and hormones.

These chemical messengers signal individual organs to change their functions in order to maintain homeostasis for the whole body. For instance, if blood oxygen levels are too low, the brain signals the muscles controlling the lungs to breathe faster to increase oxygen intake.